Infiltrative Cardiovascular Diseases. Cardiomyopathies That Look Alike

Journal of the American College of Cardiology

Volumn 55, Issue 17, 2010, Pages 1769-1779

  Seward, James B ^a   Casaclang Verzosa, Grace ^b  

^a Mayo Clinic   (United States)

^b Mayo Clinic College of Medicine   (United States)

Author keywords

cardiomyopathies; cardiomyopathy; infiltrative

Indexed keywords

CARDIOVASCULAR DISEASE; CONGESTIVE CARDIOMYOPATHY; DANON DISEASE; DIFFERENTIAL DIAGNOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FABRY DISEASE; FRIEDREICH ATAXIA; GENETIC SCREENING; HEART AMYLOIDOSIS; HEART ANEURYSM; HEART ELECTROPHYSIOLOGY; HEART FUNCTION TEST; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART LEFT VENTRICLE WALL MOTION; HEART VENTRICLE FILLING; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE VOLUME; HEART VENTRICLE WALL; HEMOCHROMATOSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; MUCOPOLYSACCHARIDOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OXALOSIS; PRIORITY JOURNAL; QRS COMPLEX; REVIEW; SARCOIDOSIS; WEGENER GRANULOMATOSIS;

CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; ELECTROCARDIOGRAPHY; HUMANS;

EID: 77950891179     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.12.040     Document Type: Review

References (84)

1. Appleton C.P. Evaluation of diastolic function by two-dimensional and Doppler assessment of left ventricular filling including pulmonary venous flow. In: Klein A.L., and Garcia M.J. (Eds). Klein & Garcia Diastology: Clinical Approach to Diastolic Heart Failure (2008), Saunders Elsevier, Philadelphia, PA 115-143
2. Oh J.K., Seward J.B., and Tajik A.J. The Echo Manual. 3rd edition (2006), Lippincott Williams & Wilkins, Philadelphia, PA
3. Vohringer M., Mahrholdt H., Yilmaz A., and Sechtem U. Significance of late gadolinium enhancement in cardiovascular magnetic resonance imaging (CMR). Herz 32 (2007) 129-137
4. Rudolph A., Abdel-Aty H., Bohl S., et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 53 (2009) 284-291
5. Chung W.K. Predictive genetic testing for cardiomyopathies. Prog Pediatr Cardiol 23 (2007) 33-38
6. Colombo M.G., Botto N., Vittorini S., Paradossi U., and Andreassi M.G. Clinical utility of genetic tests for inherited hypertrophic and dilated cardiomyopathies. Cardiovasc Ultrasound 6 (2008) 62
7. Gertz M.A., Lacy M.Q., and Dispenzieri A. Amyloidosis: recognition, confirmation, prognosis, and therapy. Mayo Clin Proc 74 (1999) 490-494
8. Klein A.L., Hatle L.K., Burstow D.J., et al. Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 13 (1989) 1017-1026
9. Bellavia D., Abraham T.P., Pellikka P.A., et al. Detection of left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. J Am Soc Echocardiogr 20 (2007) 1194-1202
10. Carroll J.D., Gaasch W.H., and McAdam K.P. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol 49 (1982) 9-13
11. Rahman J.E., Helou E.F., Gelzer-Bell R., et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 43 (2004) 410-415
12. Kumar V., Abbas A.K., Fausto N., and Mitchell R.N. Robbins Basic Pathology. 8th edition (2007), Saunders Elsevier, Philadelphia, PA
13. Kyle R.A., Gertz M.A., Greipp P.R., et al. Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood 93 (1999) 1062-1066
14. Palladini G., Russo P., Nuvolone M., et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 110 (2007) 787-788
15. Wechalekar A.D., Goodman H.J., Lachmann H.J., Offer M., Hawkins P.N., and Gillmore J.D. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 109 (2007) 457-464
16. Kastritis E., Anagnostopoulos A., Roussou M., et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 92 (2007) 1351-1358
17. Comenzo R.L., and Gertz M.A. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99 (2002) 4276-4282
18. Rajkumar S.V., Gertz M.A., Kyle R.A., and Greipp P.R. Current therapy for multiple myeloma. Mayo Clin Proc 77 (2002) 813-822
19. Gertz M.A., Lacy M.Q., Gastineau D.A., et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 26 (2000) 963-969
20. Lacy M.Q., Dispenzieri A., Hayman S.R., et al. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. J Heart Lung Transplant 27 (2008) 823-829
21. Maurer M.S., Raina A., Hesdorffer C., et al. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation 83 (2007) 539-545
22. Goldman M.E., Cantor R., Schwartz M.F., Baker M., and Desnick R.J. Echocardiographic abnormalities and disease severity in Fabry's disease. J Am Coll Cardiol 7 (1986) 1157-1161
23. Nakao S., Takenaka T., Maeda M., et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333 (1995) 288-293
24. Pieroni M., Chimenti C., De Cobelli F., et al. Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol 47 (2006) 1663-1671
25. Colucci W.S., Lorell B.H., Schoen F.J., Warhol M.J., and Grossman W. Hypertrophic obstructive cardiomyopathy due to Fabry's disease. N Engl J Med 307 (1982) 926-928
26. Ommen S.R., Nishimura R.A., and Edwards W.D. Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy?. Heart 89 (2003) 929-930
27. Kounas S., Demetrescu C., Pantazis A.A., et al. The binary endocardial appearance is a poor discriminator of Anderson-Fabry disease from familial hypertrophic cardiomyopathy. J Am Coll Cardiol 51 (2008) 2058-2061
28. De Cobelli F., Esposito A., Belloni E., et al. Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy. AJR Am J Roentgenol 192 (2009) W97-W102
29. Pochis W.T., Litzow J.T., King B.G., and Kenny D. Electrophysiologic findings in Fabry's disease with a short PR interval. Am J Cardiol 74 (1994) 203-204
30. Linhart A., Lubanda J.C., Palecek T., et al. Cardiac manifestations in Fabry disease. J Inherit Metab Dis 24 Suppl (2001) 75-83
31. Eng C.M., Guffon N., Wilcox W.R., et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J Med 345 (2001) 9-16
32. Arad M., Maron B.J., Gorham J.M., et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 352 (2005) 362-372
33. Sugimoto S., Shiomi K., Yamamoto A., Nishino I., Nonaka I., and Ohi T. LAMP-2 positive vacuolar myopathy with dilated cardiomyopathy. Intern Med 46 (2007) 757-760
34. Charron P., Villard E., Sebillon P., et al. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart 90 (2004) 842-846
35. Sugie K., Yamamoto A., Murayama K., et al. Clinicopathological features of genetically confirmed Danon disease. Neurology 58 (2002) 1773-1778
36. Piotrowska-Kownacka D., Kownacki L., Kuch M., et al. Cardiovascular magnetic resonance findings in a case of Danon disease. J Cardiovasc Magn Reson 11 (2009) 12
37. Arad M., Benson D.W., Perez-Atayde A.R., et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest 109 (2002) 357-362
38. Arad M., Moskowitz I.P., Patel V.V., et al. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 107 (2003) 2850-2856
39. Echaniz-Laguna A., Mohr M., Epailly E., et al. Novel Lamp-2 gene mutation and successful treatment with heart transplantation in a large family with Danon disease. Muscle Nerve 33 (2006) 393-397
40. Durr A., Cossee M., Agid Y., et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med 335 (1996) 1169-1175
41. Child J.S., Perloff J.K., Bach P.M., Wolfe A.D., Perlman S., and Kark R.A. Cardiac involvement in Friedreich's ataxia: a clinical study of 75 patients. J Am Coll Cardiol 7 (1986) 1370-1378
42. Morvan D., Komajda M., Doan L.D., et al. Cardiomyopathy in Friedreich's ataxia: a Doppler-echocardiographic study. Eur Heart J 13 (1992) 1393-1398
43. Dutka D.P., Donnelly J.E., Nihoyannopoulos P., Oakley C.M., and Nunez D.J. Marked variation in the cardiomyopathy associated with Friedreich's ataxia. Heart 81 (1999) 141-147
44. Alboliras E.T., Shub C., Gomez M.R., et al. Spectrum of cardiac involvement in Friedreich's ataxia: clinical, electrocardiographic and echocardiographic observations. Am J Cardiol 58 (1986) 518-524
45. Leone M., Rocca W.A., Rosso M.G., Mantel N., Schoenberg B.S., and Schiffer D. Friedreich's disease: survival analysis in an Italian population. Neurology 38 (1988) 1433-1438
46. Boddaert N., Le Quan Sang K.H., Rotig A., et al. Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110 (2007) 401-408
47. Isnard R., Kalotka H., Durr A., et al. Correlation between left ventricular hypertrophy and GAA trinucleotide repeat length in Friedreich's ataxia. Circulation 95 (1997) 2247-2249
48. Gilbert E.F. The effects of metabolic diseases on the cardiovascular system. Am J Cardiovasc Pathol 1 (1987) 189-213
49. Schulze M.R., Wachter R., Schmeisser A., Fischer R., and Strasser R.H. Restrictive cardiomyopathy in a patient with primary hyperoxaluria type II. Clin Res Cardiol 95 (2006) 235-240
50. Palka P., Duhig E., Carey L., and Galbraith A. Primary oxalosis with cardiac involvement: echocardiographic features of an unusual form of cardiomyopathy. Circulation 103 (2001) E122-E123
51. Velez-Roa S., Depierreux M., Nortier J., and Unger P. Cardiac oxalosis: a rare cause of diastolic dysfunction. Eur Heart J 27 (2006) 2496
52. Detry O., Honore P., DeRoover A., et al. Reversal of oxalosis cardiomyopathy after combined liver and kidney transplantation. Transpl Int 15 (2002) 50-52
53. Schieken R.M., Kerber R.E., Ionasescu V.V., and Zellweger H. Cardiac manifestations of the mucopolysaccharidoses. Circulation 52 (1975) 700-705
54. Hamosh A. Online Mendelian Inheritance in Men (2004), Johns Hopkins University, Baltimore, MD
55. Wraith J. The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Child 72 (1995) 263-267
56. Rigante D., and Segni G. Cardiac structural involvement in mucopolysaccharidoses. Cardiology 98 (2002) 18-20
57. Dangel J. Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders-clinical and echocardiographic findings in 64 patients. Eur J Pediatr 157 (1998) 534-538
58. Butman S.M., Karl L., and Copeland J.G. Combined aortic and mitral valve replacement in an adult with Scheie's disease. Chest 96 (1989) 209-210
59. Kitabayashi K., Matsumiya G., Ichikawa H., Matsue H., Shimamura K., and Sawa Y. Surgical treatment for mitral stenosis in Scheie's syndrome: mucopolysaccharidosis type I-S. Ann Thorac Surg 84 (2007) 654-655
60. Gatzoulis M., Vellodi A., and Redington A. Cardiac involvement in mucopolysaccharidoses: effects of allogeneic bone marrow transplantation. Arch Dis Child 73 (1995) 259-260
61. Herskhovitz E., Yount E., Rainer J., et al. Bone marrow transplantation for Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI): long-term follow-up. J Inherit Metab Dis 22 (1999) 50-62
62. Deng J.C., Baughman R.P., and Lynch III J.P. Cardiac involvement in sarcoidosis. Semin Respir Crit Care Med 23 (2002) 513-527
63. Hourigan L.A., Burstow D.J., Pohlner P., Clarke B.E., and Donnelly J.E. Transesophageal echocardiographic abnormalities in a case of cardiac sarcoidosis. J Am Soc Echocardiogr 14 (2001) 399-402
64. Silverman K.J., Hutchins G.M., and Bulkley B.H. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 58 (1978) 1204-1211
65. Yazaki Y., Isobe M., Hiramitsu S., et al. Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. Am J Cardiol 82 (1998) 537-540
66. Baughman R.P. Pulmonary hypertension associated with sarcoidosis. Arthritis Res Ther 9 Suppl (2007) S8
67. Shah L. Lung transplantation in sarcoidosis. Semin Respir Crit Care Med 28 (2007) 134-140
68. Doughan A.R., and Williams B.R. Cardiac sarcoidosis. Heart 92 (2006) 282-288
69. Tadamura E., Yamamuro M., Kubo S., et al. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. AJR Am J Roentgenol 185 (2005) 110-115
70. Smedema J.P., Snoep G., van Kroonenburgh M.P., et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 45 (2005) 1683-1690
71. Wallace D., Lott M.T., and Procaccio V. Mitochondrial genes in degenerative disease, cancer and aging. In: Rimoin D.L., Connor J.M., Pyeritz R.E., and Korf B.R. (Eds). Emery and Rimoin's Principles and Practice of Medical Genetics. 5th edition (2007), Churchill Livingston, Philadelphia, PA 194-298
72. Baughman R.P., Costabel U., and du Bois R.M. Treatment of sarcoidosis. Clin Chest Med 29 (2008) 533-548
73. Hoffman G.S., Kerr G.S., Leavitt R.Y., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116 (1992) 488-498
74. Oliveira G.H., Seward J.B., Tsang T.S., and Specks U. Echocardiographic findings in patients with Wegener granulomatosis. Mayo Clin Proc 80 (2005) 1435-1440
75. Edwards N.C., Ferro C.J., Townend J.N., and Steeds R.P. Myocardial disease in systemic vasculitis and autoimmune disease detected by cardiovascular magnetic resonance. Rheumatology 46 (2007) 1208-1209
76. Seo P., Min Y.I., Holbrook J.T., et al. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 52 (2005) 2168-2178
77. Cheong B., Huber S., Muthupillai R., and Flamm S.D. Evaluation of myocardial iron overload by T2* cardiovascular magnetic resonance imaging. Tex Heart Inst J 32 (2005) 448-449
78. Masci P.G., Dymarkowski S., and Bogaert J. The role of cardiovascular magnetic resonance in the diagnosis and management of cardiomyopathies. J Cardiovasc Med (Hagerstown) 9 (2008) 435-449
79. Hoffbrand A.V. Diagnosing myocardial iron overload. Eur Heart J 22 (2001) 2140-2141
80. Qaseem A., Aronson M., Fitterman N., Snow V., Weiss K.B., and Owens D.K. Screening for hereditary hemochromatosis: a clinical practice guideline from the American College of Physicians. Ann Intern Med 143 (2005) 517-521
81. Nishio M., Endo T., Nakao S., Sato N., and Koike T. Reversible cardiomyopathy due to secondary hemochromatosis with multitransfusions for severe aplastic anemia after successful non-myeloablative stem cell transplantation. Int J Cardiol 127 (2008) 400-401
82. Blank R., Wolber T., Maeder M., and Rickli H. Reversible cardiomyopathy in a patient with juvenile hemochromatosis. Int J Cardiol 111 (2006) 161-162
83. Alexander J., and Kowdley K.V. Hereditary hemochromatosis: genetics, pathogenesis, and clinical management. Ann Hepatol 4 (2005) 240-247
84. Ocel J.J., Edwards W.D., Tazelaar H.D., Petrovic L.M., Edwards B.S., and Kamath P.S. Heart and liver disease in 32 patients undergoing biopsy of both organs, with implications for heart or liver transplantation. Mayo Clin Proc 79 (2004) 492-501